Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2022 call → NOWe need to determine if management conveys that successive engagements of the same kind are coming in at progressively larger size. Look for statements about deals, orders, contracts, projects, customers, sites, programs being individually bigger, broader, longer than before. Scan transcript for such language. Sanjiv mentions project backlog opportunities, recent wins for electronics, potential new U.S. Gulf Coast projects, blue hydrogen. He says "there are several projects we expect to sign before the year end, which could take this number close to the 4 billion mark, even after starting up close to 1 billion in projects during the course of the year." That's about backlog size, not necessarily unit size escalation. He talks about engineering order intake of about $1 billion in last quarter. Not about size escalation. He mentions oxyfuel wins: "10 wins already in the first half. We've got at least 15 to 20 other proposals that we're working on." That's more wins, not larger size. He talks about U.S. packaged gas business growing, but not about individual deal size. He mentions electronics wins, but no comparison of size. He mentions hydrogen projects: "between 290 to 300 projects" and "20 billion potential" but not about individual project size increasing. No statement like "average deal size has increased" or "new customers are starting at larger scale" or "follow-on orders are multiples." Management does not convey that the unit size of its repeatable business is escalating. They talk about strong demand, more projects, but not about each new instance being larger. Thus answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.